Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$760K Buy
17,821
+3,456
+24% +$154K 0.13% 123
2026
Q1
$692K Buy
14,365
+6,688
+87% +$312K 0.15% 118
2025
Q4
$372K Sell
7,677
-496
-6% -$24.6K 0.09% 248
2025
Q3
$386K Buy
+8,173
New +$394K 0.16% 124
2025
Q2
Sell
-4,448
Closed -$247K 321
2025
Q1
$247K Sell
4,448
-6,542
-60% -$354K 0.15% 131
2024
Q4
$530K Buy
10,990
+194
+2% +$9.86K 0.34% 42
2024
Q3
$622K Buy
10,796
+534
+5% +$28.8K 0.41% 36
2024
Q2
$498K Sell
10,262
-319
-3% -$15.4K 0.35% 45
2024
Q1
$514K Sell
10,581
-351
-3% -$17.1K 0.38% 40
2023
Q4
$544K Buy
+10,932
New +$535K 0.46% 33

Other funds holding SNY

Abel Hall LLC's SNY Position: Q2 2026 in Review

Abel Hall LLC increased its Sanofi (SNY) stake by 24% in Q2 2026, buying an estimated $154K and bringing the position to 17,821 shares worth $760K. The position accounts for 0.13% of the portfolio, ranked #123.

Abel Hall LLC first reported a position in SNY in Q4 2023 and has held it in 10 quarters since. 715 funds tracked by Wall St. Rank hold SNY as of Q2 2026.

  • Abel Hall LLC held 17,821 shares of Sanofi worth $760K as of Q2 2026.
  • Abel Hall LLC bought 3,456 Sanofi shares in Q2 2026, an estimated $154K.
  • Sanofi made up 0.13% of Abel Hall LLC's portfolio in Q2 2026, its #123 holding.
  • Abel Hall LLC first reported a position in Sanofi in Q4 2023 and has held it in 10 quarters since.
  • 715 funds tracked by Wall St. Rank held Sanofi as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.